Cookies help us deliver our services. By using our services, you agree to our use of cookies.
Learn more
OK
Skip to main content (Press Enter).
Sign In
Skip auxiliary navigation (Press Enter).
Contact Us
Skip main navigation (Press Enter).
Toggle navigation
Search Options
About
What is the AMS
AMS International Scientific Committee
AMS Educational Executive Committee
AMS Ambassadors
Certification & Accreditation
Upcoming Events
Videos & Webinars
International Events
Become a Speaker
Videos On Demand
Education 365
Features
AMS Features
Blogs
Industry
Industry Partners
Become a Sponsor
Features
Blogs
Blog Viewer
Blogs
Laboratory safety of dupilumab for up to 3 years in adults with moderate-to-severe atopic dermatitis: results from an open-label extension study
By
- AMS
posted
Feb 09, 2021 07:11 AM
0
Recommend
.
0 comments
0 views
Related Content
Dupilumab provides rapid and sustained improvement in SCORAD outcomes in adults with moderate-to-severe atopic dermatitis: combined results of four randomized phase 3 trials
- AMS
Added Jun 08, 2020
Blog Entry
A 48-week update of a multicentre real-life experience of dupilumab in adult patients with moderate-to-severe atopic dermatitis
- AMS
Added Jul 03, 2020
Blog Entry
Restylane Celebrates 25 Years of Natural Looking Results with Its Signature Line of Hyaluronic Acid Fillers
- AMS
Added Oct 20, 2021
Blog Entry
Improvement in sleep and itch and enhanced quality of life in adult patients with moderate-to-severe atopic dermatitis: results from a phase 3 trial of baricitinib therapy
- AMS
Added Jun 28, 2021
Blog Entry
FDA Strengthens Safety Requirements and Updates Study Results for Breast Implants
- AMS
Added Nov 10, 2021
Blog Entry
Permalink
© 2022 AMS, Aesthetic Multispecialty Society. All Rights Reserved.
Powered by Higher Logic